{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:25:27Z","timestamp":1790810727112,"version":"4.1.0"},"reference-count":26,"publisher":"S. Karger AG","issue":"7-8","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>Introduction: Addition of cyclin-dependent 4\/6 kinase (CDK4\/6) inhibitors to endocrine therapy is standard of care in the treatment of women with advanced hormone receptor-positive HER2-negative breast cancer. However, the predictive factors for the treatment response to CDK4\/6 inhibitor therapy are poorly elucidated. Early changes in the by [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) uptake of tumors receiving different kinds of therapy have proven to reliably predict treatment outcomes in a variety of malignancies. Therefore, the feasibility of early metabolic response assessment to predict the long-term treatment response to CDK4\/6 inhibitor therapy was evaluated in the present study. Methods: Eight patients underwent FDG-PET\/CT before and after the initiation of CDK4\/6 inhibitor therapy (ribociclib, palbociclib or abemcaciclib). CDK4\/6 inhibitor therapy was combined with either aromatase inhibition or fulvestrant. The median interval between the treatment start (including baseline PET) and the follow-up PET examination was 14 days. Conventional radiographic staging was performed 3 months after the start of CDK4\/6 inhibitor therapy. The percentual changes in molecular tumor volume, SUVpeak, the summed SUVpeak of up to 5 metastases (PERCIST-5), and total lesion glycolysis (TLG) were calculated for each patient. Results: Three patients showed progressive disease after 3 months of CDK4\/6 inhibitor therapy, whereas 5 patients showed disease control (3 stable disease and 2 partial remission). Disease control was maintained in these patients (follow-up range 7\u201322 months). Patients with disease control had a significantly greater decline in TLG (\u201355.3 vs. 16.7%; p &lt; 0.05). The same was true for the PERCIST-5 (\u201321.9 vs. 11.3%, p &lt; 0.05). All patients with progressive TLG showed treatment failure and\/or a poor outcome. Conclusion: Elevated TLG on early FDG-PET seems to be associated with long-term treatment failure and a poor outcome in patients undergoing CDK4\/6 inhibitor therapy for metastatic breast cancer. Early findings indicate a potential prognostic value of early FDG-PET in this setting and warrant a prospective evaluation. <\/jats:p>","DOI":"10.1159\/000516422","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T21:00:40Z","timestamp":1623186040000},"page":"400-407","source":"Crossref","is-referenced-by-count":23,"title":["[18F]-Fluorodeoxyglucose Positron Emission Tomography\/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4\/6 Kinase Inhibitors"],"prefix":"10.1159","volume":"44","author":[{"given":"Robert","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"K\u00fcper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Tewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heuschmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Welt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang\u00a0P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-8775","authenticated-orcid":false,"given":"Thomas","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170330120452"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3920"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00613-0"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy012"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092480"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0934"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.188839"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70244-9"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS1105"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03215-x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70475-9"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.0518"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-452"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1055\/a-0891-7650"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-018-01323-8"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000518"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/0284185114539786"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.18.19602"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000246847.02058.1b"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/ort\/article-pdf\/44\/7-8\/400\/3899065\/000516422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/ort\/article-pdf\/44\/7-8\/400\/3899065\/000516422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:55:38Z","timestamp":1745420138000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000516422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":26,"journal-issue":{"issue":"7-8","published-online":{"date-parts":[[2021,8,3]]},"published-print":{"date-parts":[[2021,8,16]]}},"URL":"https:\/\/doi.org\/10.1159\/000516422","archive":["Portico"],"relation":{},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}